keyword
MENU ▼
Read by QxMD icon Read
search

hepatitis a b c d e f

keyword
https://www.readbyqxmd.com/read/29680842/one-or-two-ligatures-inducing-periodontitis-are-sufficient-to-cause-fatty-liver
#1
L-S Pessoa, F-R Pereira-da Silva, E-H-P Alves, L-F-C Franca, D di Lenardo, J-S Carvalho, V-B-D Martins, F-B-M Sousa, K-O Drumond, J-V-R Medeiros, J-S de Oliveira, D-F-P Vasconcelos
BACKGROUND: Periodontitis is a chronic disease that due to an intense inflammatory response triggers systemic changes such as hepatic alterations. This study aimed to compare hepatic damage in rats that received experimental periodontitis at one or two periodontal sites with ligatures. MATERIAL AND METHODS: Eighteen rats were separated into three groups: control, without ligature; periodontitis 1, with one ligature; and periodontitis 2, with two ligatures. The following parameters were assessed: gingival bleeding index, probing pocket depth, tooth mobility, alveolar bone loss, malondialdehyde (MDA) and myeloperoxidase (MPO) activity in periodontal tissue; histopathological evaluation of hepatic tissue (steatosis score); glutathione levels (GSH), MDA, MPO, cholesterol and triglycerides in the liver; and serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST)...
April 22, 2018: Medicina Oral, Patología Oral y Cirugía Bucal
https://www.readbyqxmd.com/read/29680650/feeding-increasing-amounts-of-ruminally-protected-choline-decreased-fatty-liver-in-nonlactating-pregnant-holstein-cows-in-negative-energy-status
#2
M G Zenobi, T L Scheffler, J E Zuniga, M B Poindexter, S R Campagna, H F Castro Gonzalez, A T Farmer, B A Barton, J E P Santos, C R Staples
The objectives were to determine the optimal feeding amount of choline in a ruminally protected form to reduce the triacylglycerol (TAG) concentration in liver and to increase TAG in blood plasma of dairy cows. Pregnant, nonlactating multiparous Holstein cows (n = 77) were blocked by body condition score (3.59 ± 0.33) and assigned to treatment at 64 ± 10 d before calculated calving date. Dietary treatments were top-dressing of 0, 30, 60, 90, or 120 g/d of ruminally protected choline (RPC; Balchem Corp., New Hampton, NY) ions to supply the equivalent of 0, 6...
April 18, 2018: Journal of Dairy Science
https://www.readbyqxmd.com/read/29665081/safety-of-sofosbuvir-based-regimens-after-liver-transplantation-longitudinal-assessment-of-renal-function-in-the-prospective-anrs-co23-cupilt-study
#3
R Anty, G Favre, A Coilly, E Rossignol, P Houssel-Debry, C Duvoux, V De Ledinghen, V Di Martino, V Leroy, S Radenne, N Kamar, V Canva, L D'Alteroche, F Durand, J Dumortier, P Lebray, C Besch, A Tran, C M Canivet, D Botta-Fridlund, H Montialoux, C Moreno, F Conti, C Silvain, P Perré, F Habersetzer, A Abergel, M Debette-Gratien, S Dharancy, V L M Esnault, C Fougerou-Leurent, C Cagnot, A Diallo, A Veislinger, H Danjou, D Samuel, G-P Pageaux, J-C Duclos-Vallée
BACKGROUND: In liver transplant recipients with hepatitis C virus recurrence, there is concern about renal safety of sofosbuvir-based regimens. Changes in serum creatinine or in the estimated glomerular filtration rate (eGFR) under treatment are used to look for possible renal toxicity. However, serum creatinine and eGFR are highly variable. AIM: To analyse renal function trajectory with numerous assays of serum creatinine over a long period of time. METHODS: In a multicentre cohort of 139 patients, the eGFR was obtained from serum creatinine using the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation...
April 17, 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29664906/cigarette-smoking-is-a-risk-factor-for-the-onset-of-fatty-liver-disease-in-nondrinkers-a-longitudinal-cohort-study
#4
Masashi Okamoto, Teruki Miyake, Kohichiro Kitai, Shinya Furukawa, Shin Yamamoto, Hidenori Senba, Sayaka Kanzaki, Akiko Deguchi, Mitsuhito Koizumi, Toru Ishihara, Hiroaki Miyaoka, Osamu Yoshida, Masashi Hirooka, Teru Kumagi, Masanori Abe, Bunzo Matsuura, Yoichi Hiasa
BACKGROUND: The effect of cigarette smoking on the onset of nonalcoholic fatty liver disease (NAFLD) is unclear, especially that associated with drinking small amounts of alcohol. We conducted a longitudinal study to investigate the relationship between cigarette smoking and NAFLD onset, which was stratified according to the amount of alcohol consumed. METHODS: We enrolled 7,905 Japanese subjects who had received annual health checkups more than twice between April 2003 and August 2013, 4,045 of whom met at least one of the following exclusion criteria and were excluded: (a) fatty liver at baseline; (b) hepatitis B or hepatitis C; (c) alcohol consumption (men: ≥210 g/wk; women: ≥140 g/wk); (d) change in alcohol drinking status between baseline and the study's endpoint; (e) change in cigarette smoking habits between baseline and the study's endpoint; or (f) current treatment with antidiabetic agents, antihypertensive agents, and/or lipid-lowering agents...
2018: PloS One
https://www.readbyqxmd.com/read/29659672/adi-peg-20-plus-best-supportive-care-versus-placebo-plus-best-supportive-care-in-patients-with-advanced-hepatocellular-carcinoma
#5
G Abou-Alfa, S Qin, B-Y Ryoo, S-N Lu, C-J Yen, Y-H Feng, H Y Lim, F Izzo, M Colombo, D Sarker, L Bolondi, G Vaccaro, W P Harris, Z Chen, R A Hubner, T Meyer, W Sun, J J Harding, E M Hollywood, J Ma, P J Wan, M Ly, J Bomalaski, A Johnston, C-C Lin, Y Chao, L-T Chen
Background: Arginine depletion is a putative target in hepatocellular carcinoma (HCC). HCC often lacks argininosuccinate synthetase, a citrulline to arginine-repleting enzyme. ADI-PEG 20 is a cloned arginine degrading enzyme - arginine deiminase - conjugated with polyethylene glycol. The goal of this study was to evaluate this agent as a potential novel therapeutic for HCC after first line systemic therapy. Methods and Patients: Patients with histologically proven advanced HCC and Child-Pugh up to B7 with prior systemic therapy, were randomized 2:1 to ADI-PEG 20 18 mg/m2 vs...
April 5, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29520872/responses-are-durable-for-up-to-5-years-after-completion-of-peginterferon-alfa-2a-treatment-in-hepatitis-b-e-antigen-positive-patients
#6
W-L Chuang, J Jia, H L Y Chan, K-H Han, T Tanwandee, D Tan, X Chen, E Gane, T Piratvisuth, L Chen, Q Xie, J J-Y Sung, D Messinger, C Wat, G Bakalos, Y F Liaw
BACKGROUND: In the large randomised NEPTUNE study, peginterferon alfa-2a 180 μg/wk for 48 weeks produced higher hepatitis B e antigen (HBeAg) seroconversion rates 24 weeks post-treatment (36%) than a lower dose (90 μg/wk) and/or shorter duration (24 weeks) (range 14%-26%). AIM: To determine seroconversion rates 5 years after completion of treatment in NEPTUNE. METHODS: HBeAg-positive patients who completed 24 weeks' follow-up in NEPTUNE (with peginterferon alfa-2a 90 μg/wk × 24 weeks [group 1]; 180 μg/wk × 24 weeks [2]; 90 μg/wk × 48 weeks [3] or 180 μg/wk × 48 weeks [4]) were followed up...
March 9, 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29508946/hepatitis-c-the-beginning-of-the-end-key-elements-for-successful-european-and-national-strategies-to-eliminate-hcv-in-europe
#7
REVIEW
G V Papatheodoridis, A Hatzakis, E Cholongitas, R Baptista-Leite, I Baskozos, J Chhatwal, M Colombo, H Cortez-Pinto, A Craxi, D Goldberg, C Gore, A Kautz, J V Lazarus, L Mendão, M Peck-Radosavljevic, H Razavi, E Schatz, N Tözün, P van Damme, H Wedemeyer, Y Yazdanpanah, F Zuure, M P Manns
Hepatitis C virus (HCV) infection is a major public health problem in the European Union (EU). An estimated 5.6 million Europeans are chronically infected with a wide range of variation in prevalence across European Union countries. Although HCV continues to spread as a largely "silent pandemic," its elimination is made possible through the availability of the new antiviral drugs and the implementation of prevention practices. On 17 February 2016, the Hepatitis B & C Public Policy Association held the first EU HCV Policy Summit in Brussels...
March 2018: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29507493/procarbazine-lomustine-and-vincristine-toxicity-in-low-grade-gliomas
#8
G Jutras, K Bélanger, N Letarte, J-P Adam, D Roberge, B Lemieux, É Lemieux-Blanchard, L Masucci, C Ménard, J P Bahary, R Moumdjian, F Berthelet, M Florescu
Background: Procarbazine, lomustine, and vincristine (pcv) significantly improve survival outcomes in lgg (low-grade gliomas). Administration of pcv to lgg patients increased tremendously over the past years as it went from 2 patients per year between 2005 and 2012 to 23 patients in 2015 only in our centre. However, serious hematological and non-hematological adverse events may occur. The purpose of this study was to evaluate the toxicity of pcv and its clinical relevance in our practice...
February 2018: Current Oncology
https://www.readbyqxmd.com/read/29498078/stopping-nucleos-t-ide-analogue-treatment-in-caucasian-hepatitis-b-patients-after-hbeag-seroconversion-is-associated-with-high-relapse-rates-and-fatal-outcomes
#9
S Van Hees, S Bourgeois, H Van Vlierberghe, T Sersté, S Francque, P Michielsen, D Sprengers, H Reynaert, J Henrion, S Negrin Dastis, J Delwaide, L Lasser, J Decaestecker, H Orlent, F Janssens, G Robaeys, I Colle, P Stärkel, C Moreno, F Nevens, T Vanwolleghem
BACKGROUND: Stopping nucleos(t)ide analogues (NA) after hepatitis B e antigen (HBeAg) seroconversion is associated with high relapse rates in Asian patients, but data in Caucasian cohorts are scarce. Clinical course, outcomes and immunological aspects of chronic hepatitis B infections differ substantially between distinct ethnicities. AIM: The aim of this study was to determine relapse rates, factors predicting relapse and clinical outcomes after nucleos(t)ide analogue cessation in a large, predominantly Caucasian cohort of chronic hepatitis B patients with nucleos(t)ide analogue-induced HBeAg seroconversion...
March 2, 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29433087/chromium-accumulation-and-biomarker-responses-in-the-neotropical-fish-prochilodus-lineatus-caged-in-a-river-under-the-influence-of-tannery-activities
#10
Bruna Lunardelli, Millena T Cabral, Carlos E D Vieira, Luciana F Oliveira, Wagner E Risso, Paulo C Meletti, Claudia B R Martinez
In order to assess the effects of tannery effluents (TE) in organism health, juveniles of Prochilodus lineatus were submitted to in situ tests at four different river locations: site A - upstream of the tannery; site B - next to the tannery; and sites C and D - downstream of the tannery. After 96 h exposure in the river, samples of fish tissue, river water and sediment were collected in order to quantify chromium (Cr) concentrations. Tissue samples were used to assess the activity of ethoxyresorufin-O-deethylase (EROD) and glutathione S-transferase (GST), the content of glutathione (GSH) and metallothionein (MT) and the occurrence of lipid peroxidation (LPO) and DNA damage...
February 9, 2018: Ecotoxicology and Environmental Safety
https://www.readbyqxmd.com/read/29408986/nivolumab-versus-docetaxel-in-previously-treated-advanced-non-small-cell-lung-cancer-checkmate-017-and-checkmate-057-3-year-update-and-outcomes-in-patients-with-liver-metastases
#11
E E Vokes, N Ready, E Felip, L Horn, M A Burgio, S J Antonia, O Arén Frontera, S Gettinger, E Holgado, D Spigel, D Waterhouse, M Domine, M Garassino, L Q M Chow, G Blumenschein, F Barlesi, B Coudert, J Gainor, O Arrieta, J Brahmer, C Butts, M Steins, W J Geese, A Li, D Healey, L Crinò
Background: Long-term data with immune checkpoint inhibitors in non-small-cell lung cancer (NSCLC) are limited. Two phase III trials demonstrated improved overall survival (OS) and a favorable safety profile with the anti-programmed death-1 antibody nivolumab versus docetaxel in patients with previously treated advanced squamous (CheckMate 017) and nonsquamous (CheckMate 057) NSCLC. We report results from ≥3 years' follow-up, including subgroup analyses of patients with liver metastases, who historically have poorer prognosis among patients with NSCLC...
April 1, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29327780/systematic-review-with-meta-analysis-effectiveness-and-tolerability-of-interferon-free-direct-acting-antiviral-regimens-for-chronic-hepatitis-c-genotype-1-in-routine-clinical-practice-in-asia
#12
REVIEW
F Ji, B Wei, Y H Yeo, E Ogawa, B Zou, C D Stave, Z Li, S Dang, N Furusyo, R C Cheung, M H Nguyen
BACKGROUND: Direct-acting antiviral (DAA) regimens have shown high efficacy and tolerability for patients with HCV genotype 1/1b (GT1/1b) in clinical trials. However, robust real-world evidence of interferon (IFN)-free DAA treatment for HCV GT1-infected patients in Asia is still lacking. AIM: To systematically review and meta-analyse the effectiveness and tolerability of IFN-free DAA therapy for HCV GT1 infection in Asia. METHODS: We included studies that enrolled adult patients with HCV GT1 infection in routine clinical practice in Asia, using IFN-free DAA regimens, and reported sustained virological response (SVR) after 12/24 weeks end-of-treatment by 31 May 2017...
March 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29322599/non-invasive-evaluation-of-portal-hypertension-using-shear-wave-elastography-analysis-of-two-algorithms-combining-liver-and-spleen-stiffness-in-191-patients-with-cirrhosis
#13
L Elkrief, M Ronot, F Andrade, M Dioguardi Burgio, T Issoufaly, M Zappa, O Roux, J Bissonnette, A Payancé, D Lebrec, C Francoz, O Soubrane, D Valla, F Durand, V Vilgrain, L Castera, P-E Rautou
BACKGROUND: Two algorithms based on sequential measurements of liver and spleen stiffness using two-dimensional shearwave elastography (2D-SWE) have been recently proposed to estimate clinically significant portal hypertension (hepatic venous pressure gradient [HVPG] ≥10 mm Hg) in patients with cirrhosis, with excellent diagnostic accuracy. AIM: To validate externally these algorithms in a large cohort of patients with cirrhosis. METHODS: One hundred and ninety-one patients with stable cirrhosis (Child-Pugh class A 39%, B 29% and C 31%) who underwent liver and spleen stiffness measurements using 2D-SWE at the time of HVPG measurement were included...
March 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29315722/very-slow-decline-of-hepatitis-b-virus-surface-antigen-and-core-related-antigen-in-chronic-hepatitis-b-patients-successfully-treated-with-nucleos-t-ide-analogues
#14
Enagnon K Alidjinou, Charlotte Michel, Valérie Canva, Faïza Ajana, Didier Hober, Laurence Bocket
We investigated the decline of hepatitis B virus surface antigen (HBsAg) and core related antigen (HBcrAg) in chronic hepatitis B patients sussessfully treated with nucleos(t)ide analogues. In patients with plasma viral suppression, the baseline median levels of HBsAg and HBcrAg were 3.1 and 3.0 log U/mL, respectively. The levels in naïve patients were 4.2 and 3.6 log U/mL for HBsAg and HBcrAg, respectively. No significant decline was observed in patients with viral suppression within a year period. A low reduction was observed during the first months after treatment initiation, especially regarding HBcrAg...
May 2018: Journal of Medical Virology
https://www.readbyqxmd.com/read/29274193/efficacy-and-safety-of-6-or-8-weeks-of-simeprevir-daclatasvir-sofosbuvir-for-hcv-genotype-1-infection
#15
M S Sulkowski, J J Feld, E Lawitz, F Felizarta, A M Corregidor, O Khalid, R Ghalib, W B Smith, V Van Eygen, D Luo, L Vijgen, M Gamil, T N Kakuda, S Ouwerkerk-Mahadevan, P Van Remoortere, M Beumont
The phase 2, open-label ACCORDION (ClinicalTrials.gov: NCT02349048) study investigated the efficacy, safety and pharmacokinetics of a 6- or 8-week regimen of simeprevir, daclatasvir and sofosbuvir in treatment-naïve patients with chronic hepatitis C virus (HCV) genotype (GT) 1 infection and either early-stage fibrosis or compensated cirrhosis. Patients were assigned to treatment groups according to their fibrosis stage. Early-stage fibrosis: simeprevir 150 mg, daclatasvir 60 mg, sofosbuvir 400 mg once daily for 6 weeks; compensated cirrhosis: same regimen for 8 weeks...
December 23, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29248218/diagnostic-performance-of-cytology-for-assessment-of-hepatic-lipid-content-in-dairy-cattle
#16
M M Fry, B Yao, C Ríos, C Wong, S Mann, J A A McArt, D V Nydam, F A Leal Yepes, L Viesselmann, A Geick, K Goldin, A Jordan, E Behling-Kelly
The objective of our study was to characterize the diagnostic performance of cytology for assessing hepatic lipid content (HLC) in dairy cows by comparing microscopic evaluation of lipid vacuolation in touch imprint slide preparations of liver biopsies with quantitative measurement of triglyceride concentration ([TG]; mg/mg of wet weight) in paired biopsy samples. Our study also sought to compare the diagnostic performance of liver cytology, plasma nonesterified fatty acid concentration ([NEFA]), and plasma β-hydroxybutyrate concentration ([BHB]) derived from a measurement performed on whole blood, for assessing HLC...
February 2018: Journal of Dairy Science
https://www.readbyqxmd.com/read/29192364/liver-metastases-from-prostate-cancer-at-11c-choline-pet-ct-a-multicenter-retrospective-analysis
#17
Pietro Ghedini, I Bossert, L Zanoni, F Ceci, T Graziani, P Castellucci, V Ambrosini, F Massari, E Nobili, B Melotti, A Musto, S Zoboli, L Antunovic, M Kirienko, A Chiti, C Mosconi, A Ardizzoni, R Golfieri, S Fanti, C Nanni
AIM: During our daily clinical practice using 11C-Choline PET/CT for restaging patients affected by relapsing prostate cancer (rPCa) we noticed an unusual but significant occurrence of hypodense hepatic lesions with a different tracer uptake. Thus, we decided to evaluate the possible correlation between rPCa and these lesions as possible hepatic metastases. MATERIALS AND METHODS: We retrospectively enrolled 542 patients diagnosed with rPCa in biochemical relapse after a radical treatment (surgery and/or radiotherapy)...
November 30, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29145578/the-changing-paradigm-of-management-of-liver-abscesses-in-chronic-granulomatous-disease
#18
David M Straughan, Kaitlin C McLoughlin, John E Mullinax, Beatriz E Marciano, Alexandra F Freeman, Victoria L Anderson, Gulbu Uzel, Saїd C Azoury, Rebecca Sorber, Humair S Quadri, Harry L Malech, Suk See DeRavin, Natasha Kamal, Christopher Koh, Christa S Zerbe, Douglas B Kuhns, John I Gallin, Theo Heller, Steven M Holland, Udo Rudloff
Background: Chronic granulomatous disease (CGD) is a rare genetic disorder causing recurrent infections. Over one quarter of patients develop hepatic abscesses and liver dysfunction. Recent reports suggest disease-modifying treatment with corticosteroids is effective for these abscesses. Comparison of corticosteroid therapy to traditional invasive treatments has not been performed. Methods: Records of 268 patients with CGD treated at the National Institutes of Health (NIH) from 1980 to 2014 were reviewed...
November 14, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29105286/strategies-to-manage-hepatitis-c-virus-infection-disease-burden-volume-4
#19
D S Chen, W Hamoudi, B Mustapha, J Layden, A Nersesov, T Reic, V Garcia, C Rios, L Mateva, O Njoya, S A Al-Busafi, M K Abdelmageed, M Abdulla, D Adda, O Akin, A Al Baqali, N Al Dweik, K Al Ejji, I Al Ghazzawi, S Al Kaabi, K Al Naamani, J Al Qamish, M Al Sadadi, J Al Salman, M AlBadri, H E Al-Romaihi, W Ampofo, K Antonov, C Anyaike, F Arome, A Bane, S Blach, M M Borodo, S M Brandon, B Bright, M T Butt, I Cardenas, H L Y Chan, C J Chen, P J Chen, R N Chien, W L Chuang, D Cuellar, M Derbala, A A Elbardiny, C Estes, E Farag, J Fung, I Gamkrelidze, J Genov, Z Ghandour, M Ghuloom, B Gomez, J Gunter, J Habeeb, O Hajelssedig, S M Himatt, I Hrstic, C C Hu, C F Huang, Y T Hui, R Jahis, D Jelev, A K John, K S Kaliaskarova, Y Kamel, J H Kao, J Khamis, H Khattabi, I Khoudri, A Konysbekova, I Kotzev, M S Lai, W C Lao, M H Lee, O Lesi, M Li, A Lo, C K Loo, B Lukšić, A Maaroufi, A O Malu, R Mitova, R Mohamed, M Morović, K Murphy, H Nde, E Ngige, R Njouom, D Nonković, S Obekpa, S Oguche, E E Okolo, O Omede, C Omuemu, P Ondoa, O Opare-Sem, S Owusu-Ofori, R O Phillips, Y N Prokopenko, H Razavi, D Razavi-Shearer, K Razavi-Shearer, B Redae, T Rinke de Wit, S Robbins, L R Roberts, S J Sanad, M Sharma, M Simonova, T H Su, K Sultan, S S Tan, K Tchernev, O T Y Tsang, S Tsang, C Tzeuton, S Ugoeze, B Uzochukwu, R Vi, A Vince, H U Wani, V W S Wong, A Workneh, R Yacoub, K I Yesmembetov, M Youbi, M F Yuen, J D Schmelzer
The hepatitis C virus (HCV) epidemic was forecasted through 2030 for 17 countries in Africa, Asia, Europe, Latin America and the Middle East, and interventions for achieving the Global Health Sector Strategy on viral hepatitis targets-"WHO Targets" (65% reduction in HCV-related deaths, 90% reduction in new infections and 90% of infections diagnosed by 2030) were considered. Scaling up treatment and diagnosis rates over time would be required to achieve these targets in all but one country, even with the introduction of high SVR therapies...
October 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29105285/historical-epidemiology-of-hepatitis-c-virus-in-select-countries-volume-4
#20
A Maaroufi, A Vince, S M Himatt, R Mohamed, J Fung, O Opare-Sem, A Workneh, R Njouom, I Al Ghazzawi, M Abdulla, K S Kaliaskarova, S Owusu-Ofori, M K Abdelmageed, D Adda, O Akin, A Al Baqali, N Al Dweik, K Al Ejji, S Al Kaabi, K Al Naamani, J Al Qamish, M Al Sadadi, J Al Salman, M AlBadri, S A Al-Busafi, H E Al-Romaihi, W Ampofo, K Antonov, C Anyaike, F Arome, A Bane, S Blach, M M Borodo, S M Brandon, B Bright, M T Butt, I Cardenas, H L Y Chan, C J Chen, D S Chen, P J Chen, R N Chien, W L Chuang, D Cuellar, M Derbala, A A Elbardiny, C Estes, E Farag, I Gamkrelidze, V Garcia, J Genov, Z Ghandour, M Ghuloom, B Gomez, J Gunter, J Habeeb, O Hajelssedig, W Hamoudi, I Hrstic, C C Hu, C F Huang, Y T Hui, R Jahis, D Jelev, A K John, Y Kamel, J H Kao, J Khamis, H Khattabi, I Khoudri, A Konysbekova, I Kotzev, M S Lai, W C Lao, J Layden, M H Lee, O Lesi, M Li, A Lo, C K Loo, B Lukšić, A O Malu, L Mateva, R Mitova, M Morović, K Murphy, B Mustapha, H Nde, A Nersesov, E Ngige, O Njoya, D Nonković, S Obekpa, S Oguche, E E Okolo, O Omede, C Omuemu, P Ondoa, R O Phillips, Y N Prokopenko, H Razavi, D Razavi-Shearer, B Redae, T Reic, T Rinke de Wit, C Rios, S Robbins, L R Roberts, S J Sanad, J D Schmelzer, M Sharma, M Simonova, T H Su, K Sultan, S S Tan, K Tchernev, O T Y Tsang, S Tsang, C Tzeuton, S Ugoeze, B Uzochukwu, R Vi, H U Wani, V W S Wong, R Yacoub, K I Yesmembetov, M Youbi, M F Yuen, K Razavi-Shearer
Due to the introduction of newer, more efficacious treatment options, there is a pressing need for policy makers and public health officials to develop or adapt national hepatitis C virus (HCV) control strategies to the changing epidemiological landscape. To do so, detailed, country-specific data are needed to characterize the burden of chronic HCV infection. In this study of 17 countries, a literature review of published and unpublished data on HCV prevalence, viraemia, genotype, age and gender distribution, liver transplants and diagnosis and treatment rates was conducted, and inputs were validated by expert consensus in each country...
October 2017: Journal of Viral Hepatitis
keyword
keyword
105123
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"